Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

Jan 17 2012

• By Sue Sutter

Related Content

Pfizer Finds Backup For Aricept In Medivation’s Dimebon

Sep 03 2008

Almost All Hopes Dashed For Pfizer/Medivation's Dimebon

Apr 11 2011

Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” says Lechleiter At JP Morgan

Jan 12 2012

Medivation, Orexigen Highlight Late-Stage Strategies for Closely-Watched Drugs

May 11 2010

Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time

Nov 14 2011

Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop

Mar 03 2010

Related Companies

Medivation, Inc.

Pfizer Inc.

Eisai Co., Ltd.

Astellas Pharma, Inc.

Eli Lilly and Company

Wyeth

Johnson & Johnson

Additional Topics

Clinical Trials Drug Approval Standards BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window